Publications dans lesquelles il/elle collabore avec Mercedes Iñarrairaegui Bastarrica (34)

2024

  1. Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment

    Clinical and Molecular Hepatology, Vol. 30, Núm. 2, pp. 177-190

  2. The Impact of Portal Hypertension Assessment Method on the Outcomes of Hepatocellular Carcinoma Resection: A Meta-Analysis of Matched Cohort and Prospective Studies

    Annals of Surgery, Vol. 280, Núm. 1, pp. 46-55

2023

  1. Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab-bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study

    The Lancet. Oncology, Vol. 24, Núm. 12, pp. 1411-1422

  2. Partial Radiation Nephrectomy Using 90Y Resin Microspheres: A Treatment Option for Renal Tumors With Malignant Characteristics in Patients Not Candidates for Surgery

    Clinical Nuclear Medicine, Vol. 48, Núm. 11, pp. 960-962

2022

  1. A new animal model of atrophy–hypertrophy complex and liver damage following Yttrium-90 lobar selective internal radiation therapy in rabbits

    Scientific Reports, Vol. 12, Núm. 1

  2. Hypovitaminosis C as an unexpected cause of bleeding in a cirrhotic patient

    Medicina Clinica

  3. Nivolumab after selective internal radiation therapy for the treatment of hepatocellular carcinoma: a phase 2, single-arm study

    Journal for immunotherapy of cancer, Vol. 10, Núm. 11

2017

  1. Conversion from calcineurin Inhibitor-Based immunosuppression to mycophenolate mofetil in monotherapy reduces risk of de novo malignancies after liver transplantation

    Annals of Transplantation, Vol. 22, pp. 141-147

  2. Immune checkpoint inhibitors for the treatment of hepatocellular carcinoma

    Immunotherapy of Hepatocellular Carcinoma (Springer International Publishing), pp. 51-68

  3. NatB-mediated protein N-α-terminal acetylation is a potential therapeutic target in hepatocellular carcinoma

    Oncotarget, Vol. 8, Núm. 25, pp. 40967-40981

  4. Phase 1–2 pilot clinical trial in patients with decompensated liver cirrhosis treated with bone marrow–derived endothelial progenitor cells

    Translational Research, Vol. 188, pp. 80-91.e2

2016

  1. Factors related to increased resting energy expenditure in men with liver cirrhosis

    European Journal of Gastroenterology and Hepatology, Vol. 28, Núm. 2, pp. 139-145

2015

  1. Clinical testing of a dendritic cell targeted therapeutic vaccine in patients with chronic hepatitis C virus infection

    Molecular Therapy - Methods and Clinical Development, Vol. 2, pp. 15006

  2. Immune monitoring of immunosuppression withdrawal of liver transplant recipients

    Transplant Immunology, Vol. 33, Núm. 2, pp. 110-116

  3. Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma

    Liver International, Vol. 35, Núm. 6, pp. 1715-1721

  4. Radioembolization of hepatocellular carcinoma activates liver regeneration, induces inflammation and endothelial stress and activates coagulation

    Liver International, Vol. 35, Núm. 5, pp. 1590-1596

2014

  1. Comparación de las sondas M y XL para estimar la rigidez hepática por medio de elastografía de transición

    Gastroenterologia y Hepatologia, Vol. 37, Núm. 4, pp. 233-239

  2. Is liver biopsy necessary in the evaluation of a living donor for liver transplantation?

    Transplantation Proceedings

  3. Partial liver volume radioembolization induces hypertrophy in the spared hemiliver and no major signs of portal hypertension

    HPB, Vol. 16, Núm. 3, pp. 243-249

2013

  1. Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma

    Journal of Hepatology, Vol. 59, Núm. 4, pp. 753-761